You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)前三季度扣非淨利潤增長8.21%至17.22億元
格隆匯 10-29 17:38

格隆匯10月29日丨復星醫藥(02196.HK)發佈2019年三季度報告,今年前三季度,公司實現營業收入212.28億元(人民幣,下同),同比增長17.01%;歸屬於上市公司股東的淨利潤20.64億元,同比下降1.45%;歸屬於上市公司股東的扣除非經常性損益的淨利潤17.22億元,同比增長8.21%;基本每股收益0.81元。

公告表示,2019年第三季度,非布司他片(優立通)、匹伐他汀鈣片(邦之)、依諾肝素注射液、達託黴素等產品銷量保持較好的增長態勢,直觀復星的達芬奇機器人設備銷售開始提速,集團當季實現歸屬於上市公司股東的扣除非經常性損益的淨利潤5.55億元,同比增長41.88%;報告期內累計實現歸屬於上市公司股東的扣除非經常性損益的淨利潤17.22億元,同比增長8.21%。

由於受擬處置資產處置進度以及所持有的部分金融資產公允價值變動影響,當季非經常性損益–719.98萬元,較上年同期減少約1.5億元;報告期內累計非經常性損益為3.41億元,同比下降32.07%。綜合前述因素,報告期內歸屬於上市公司股東的淨利潤較上年同期減少3044.82萬元,同比下降1.45%。

報告期內,集團累計研發投入達22.53億元,,同比增長20.70%;經營活動現金流保持持續上升趨勢,經營活動產生的現金流量淨額23.28億元,較2018年同期增長11.52%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account